Company Home Page Yahoo FInance for XNPT
XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to enhance the therapeutic benefits of drugs. The company licenses its lead product candidate Gabapentin Enacarbil, a transported prodrug of gabapentin, to Astellas Pharma Inc. in Japan and five Asian countries, as well as to Glaxo Group Limited in the United States. Astellas Pharma Inc. filed new drug application for the approval of Gabapentin Enacarbil as a treatment for restless legs syndrome in Japan. The company also develops Arbaclofen Placarbil, which completed a Phase II clinical trial for the treatment of spasticity in patients with spinal cord injury. In addition, it develops Arbaclofen Placarbil for the treatment of gastroesophageal reflux disease. Further, the company develops XP21279, which is in Phase II clinical trial for the treatment of Parkinson's disease; and XP23829, a novel prodrug of methylhydrogenfumarate that is in preclinical stage. It has strategic alliances with Astellas Pharma, Inc. and Glaxo Group Limited. The company was founded in 1999 and is based in Santa Clara, California.
Xenoport: Favorable Risk/Reward Ratio
8/16/11 Wedbush Conference Notes by mcbio
Biotech Values Board
has some periodic discussions on the company. Old ReadMe